The protein encoded by this gene is a member of theE2F family oftranscription factors. The E2F family plays a crucial role in the control ofcell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. This protein binds to all three of the tumor suppressor proteins pRB, p107 and p130, but with higher affinity to the last two. It plays an important role in the suppression of proliferation-associated genes, and its gene mutation and increased expression may be associated with human cancer.[7]
The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include aDNA binding domain, adimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), atransactivation domain enriched in acidic amino acids (Asp +Glu), and a tumor suppressor protein association domain which is embedded within the transactivation domain.
Bandyopadhyay D, Timchenko N, Suwa T, et al. (2001). "The human melanocyte: a model system to study the complexity of cellular aging and transformation in non-fibroblastic cells".Exp. Gerontol.36 (8):1265–75.doi:10.1016/S0531-5565(01)00098-5.PMID11602203.S2CID26041753.
Williams CD, Linch DC, Sørensen TS, et al. (1997). "The predominant E2F complex in human primary haemopoietic cells and in AML blasts contains E2F-4, DP-1 and p130".Br. J. Haematol.96 (4):688–96.doi:10.1046/j.1365-2141.1997.d01-2086.x.PMID9074408.S2CID23265759.
Wang H, Shao N, Ding QM, et al. (1997). "BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases".Oncogene.15 (2):143–57.doi:10.1038/sj.onc.1201252.PMID9244350.S2CID11930784.
Furukawa Y, Iwase S, Kikuchi J, et al. (1999). "Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes".Oncogene.18 (11):2003–14.doi:10.1038/sj.onc.1202500.PMID10208422.S2CID9069532.
